TransMedics Group, Inc. (TMDX)

Healthcare · Medical Technology · Price $88.43
Updated: Aug 31, 2026
Moderate Multiple — Healthcare
P/E of 22.91x is within the 18–28x range Zyberno considers reasonable for Healthcare businesses.
P/E Ratio (TTM)
22.91x
Above average P/E - growth expectations priced in
Earnings Yield
4.37%
1 / P/E Ratio
EPS (TTM)
$3.86
Diluted Earnings Per Share
Stock Price
$88.43
Current Market Price
PEG Ratio
0.23
Potentially undervalued relative to growth
Earnings Growth
79.18%
Net Income Growth (Linear)

🧮 TMDX P/E Ratio Calculation

P/E Ratio = Stock Price ÷ Earnings Per Share (TTM)
Stock Price $88.43
÷
Earnings Per Share (TTM) $3.86
= P/E Ratio 22.91x

What is the P/E Ratio?

The Price-to-Earnings (P/E) Ratio is one of the most widely used valuation metrics. It tells you how much investors are willing to pay for each dollar of a company's earnings. Zyberno calculates P/E using trailing twelve month (TTM) diluted earnings from official SEC filings.

P/E Ratio = Stock Price ÷ Earnings Per Share (TTM)
Using diluted EPS which accounts for stock options and convertible securities

How to Interpret the P/E Ratio

Low P/E (Under 15x)

May indicate undervaluation, or the market expects declining earnings. Common in mature, slow-growth industries.

Average P/E (15-20x)

Roughly in line with historical S&P 500 average. Suggests fairly valued with moderate growth expectations.

High P/E (20-35x)

Investors expect above-average earnings growth. Common for technology companies and market leaders.

Very High P/E (35x+)

Extreme growth expectations priced in. Significant valuation risk if growth slows.

PEG Ratio: P/E Adjusted for Growth

The PEG Ratio addresses a key limitation of P/E by factoring in earnings growth. A PEG of 1.0 suggests fair value; below 1.0 may indicate undervaluation, while above 2.0 suggests a premium price for growth.

PEG Ratio = P/E Ratio ÷ Earnings Growth Rate
TMDX: 22.91x ÷ 79.18% = 0.23

P/E Ratio Limitations

The P/E ratio doesn't work for companies with negative earnings. It can be manipulated by one-time charges or gains, and it doesn't account for debt levels or growth rates. Use P/E alongside PEG ratio, EV/EBITDA, and Owner Earnings yield for a complete picture.

Comparing Valuation Metrics

EPS: $3.86 →

The denominator in the P/E calculation. Represents profit allocated to each outstanding share.

Price-to-Book: N/A

Compares stock price to book value. Useful for asset-heavy industries like banking and manufacturing.

EV/EBITDA: N/A

Accounts for debt and is useful for comparing companies with different capital structures.

Owner Earnings Yield →

Warren Buffett's preferred metric. Shows cash return to owners as a percentage of market cap.

📊 Full TMDX Stock Report

Intrinsic value, margin of safety, DCF valuation, and 250+ metrics.

📈 TMDX Earnings Per Share

Deep dive into EPS trends, quarterly history, and earnings growth analysis.

🏆 TMDX ROIC

Measure capital efficiency — how well management deploys every dollar invested.

💎 TMDX Intrinsic Value

Calculate what TMDX is truly worth using DCF and Owner Earnings models.

💵 TMDX Owner Earnings

Warren Buffett's preferred measure of true earning power and cash generation.

🛡️ TMDX Margin of Safety

See if TMDX is trading below its intrinsic value.

View Full TMDX Report Find More Quality Stocks
📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
$168.56
🛡️
Margin of Safety
Valuation Gap
47.5%
🎯
Expected Return
Projected Annual
36.5%
Click any metric for full methodology and detailed analysis

Summary: TMDX P/E Ratio

TransMedics Group, Inc. (TMDX) trades at a P/E of 22.91x, which Zyberno classifies as a moderate multiple for a Healthcare company — within the 18–28x range Zyberno considers reasonable for healthcare companies where pipeline value and patent protection justify premium multiples. Earnings yield: 4.37%.

Based on 0 quarters of SEC filings, TMDX's EPS is currently $3.86 on a trailing twelve-month basis. Zyberno cross-references the P/E ratio with business quality — a high multiple on a high-quality business (strong ROE, ROIC, and FCF) carries less risk than the same multiple on a weaker business. For complete financial analysis, view the full TMDX stock report on Zyberno.

Frequently Asked Questions

What is TMDX's current P/E Ratio?

TransMedics Group, Inc.'s trailing twelve month (TTM) P/E Ratio is 22.91x, within the context of Healthcare sector multiples where Zyberno considers 18–28x moderate. Investors are paying $22.91 for every $1 of annual earnings.

Is TMDX's P/E Ratio high or low?

TransMedics Group, Inc. (TMDX) trades at a P/E of 22.91x, which Zyberno classifies as a moderate multiple for a Healthcare company — within the 18–28x range Zyberno considers reasonable for healthcare companies where pipeline value and patent protection justify premium multiples. Earnings yield: 4.37%.

What is TMDX's earnings yield?

TMDX's earnings yield is 4.37%, which is the inverse of the P/E ratio (1 ÷ P/E). This represents the theoretical return if all earnings were distributed to shareholders.

How is P/E Ratio calculated?

P/E Ratio = Stock Price ÷ EPS. For TMDX: $88.43 ÷ $3.86 = 22.91x.

What is TMDX's PEG Ratio?

TMDX's PEG Ratio is 0.23. Potentially undervalued relative to growth. PEG below 1.0 is often considered undervalued, while above 2.0 may indicate overvaluation relative to growth.

📊 Full TMDX Stock Report

See TMDX's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

🏆 TMDX ROIC

Compare to Return on Invested Capital — the most comprehensive measure of capital efficiency.

📈 TMDX ROE

Compare to Return on Equity and understand the impact of leverage on returns.

🎯 TMDX Earnings Surprise (SUE)

See whether TMDX is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

👤 TMDX Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💰 TMDX Net Income

See the bottom-line profit that drives return calculations.

📊 TMDX EPS

Earnings per share — net income on a per-share basis.

View Full TMDX Report Find More Quality Stocks
Scroll to Top